CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM, Timmer-Bosscha H, Nagengast WB, Oude Munnink TH, Kruizinga RC, Ananias HJ, Kliphuis NM, Huls G, De Vries EG, de Jong IJ, Walenkamp AM.
Domanska UM, et al.
Neoplasia. 2012 Aug;14(8):709-18. doi: 10.1593/neo.12324.
Neoplasia. 2012.
PMID: 22952424
Free PMC article.